Skip to contents
In This Issue:
A new option for treating prostate cancer may be on the horizon, and it’s a fraction of the width of a human hair—1/1000 to be exact.
BWH’s Omid Farokhzad, MD, and his team in the Nanomedicine and Biomaterials Lab are investigating how to use tiny nanoparticles to deliver chemotherapy to cancer cells without invading and destroying healthy cells.
Thanks to a multi-institutional $5 million grant, Farokhzad will collaborate with chemical engineer Robert Langer, ScD, at MIT; medical oncologist Philip Kantoff, MD, at DFCI; and urologist Neil Bander, MD, at the Weill Medical College of Cornell University to bring nanotechnology to the bedside to treat metastatic prostate cancer, for which there is no effective treatment.
The grant, which allows the team to work on developing drug treatments for prostate cancer over the next five years, was funded through the generosity of philanthropist David H. Koch and the Prostate Cancer Foundation, which organized this unique partnership in prostate cancer research.
“The generosity of this donation will expand our resources and help our multi-institutional team move faster than we could each do alone to develop new, forward-thinking treatments for the deadliest form of prostate cancer,” BWH President Gary Gottlieb, MD, MBA, said.